Search Results

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.

Caris Life Sciences® announced an ongoing collaboration with the Beat Childhood Cancer Research Consortium, a group of over 50 universities and children’s hospitals, based at Penn State College of Medicine in Hershey, Pa., that offers a worldwide network of pediatric cancer clinical trials.

Ginkgo Bioworks announced it is joining efforts with Penn State University to integrate its biosurveillance capabilities into the university’s research of 58 wildlife species for SARS-CoV-2 to monitor potential spillover to humans.

With Alzheimer’s disease expected to afflict 12.7 million Americans by 2050, researchers at Penn State University and Duke University Medical Center are advancing our understanding of the disease’s behavior in different people – making personalized, optimized treatment possible for the first time. And they’re doing it with math.

Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center utilizing the advanced Genesis Robotic Magnetic Navigation System.

AviadoBio today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open and recruiting patients in the United States at The Ohio State University.

INOVIO announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.

PAVmed Inc announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, launched a pilot program and enrolled the first patients on the Veris Cancer Care Platform™ pursuant to a recently-executed memorandum of understanding.

Halberd Corporation’s Traumatic Brain Injury mitigating nasal spray testing protocols at Mississippi State University were approved by the Institutional Animal Care and Use Committee.